Glucocorticoids (Gcs) have been widely and successfully used to treat a broad spectrum of hematological malignancies, and the glucocorticoid receptor (GR) is a well-known anti-cancer target. Unfortunately, most patients chronically treated with Gcs develop numerous deleterious metabolic and atrophic side effects that strongly affect the quality of their life. Thus, there is a great need for the development of safer GR-targeted therapies.
|Effective start/end date||1/23/17 → 7/22/20|
- ILSI Health and Environmental Sciences Institute (Agreement 12/05/16)